Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, Reiter Y, Almog R, Halberthal M, Ben-Aharon I. Goshen-Lago T, et al. Among authors: almog r. JAMA Oncol. 2021 Oct 1;7(10):1507-1513. doi: 10.1001/jamaoncol.2021.2675. JAMA Oncol. 2021. PMID: 34236381 Free PMC article.
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors.
Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Peer A, Almog R, Shaked Y, Halberthal M, Ben-Aharon I. Waldhorn I, et al. Among authors: almog r. Cancer Discov. 2021 Oct;11(10):2430-2435. doi: 10.1158/2159-8290.CD-21-1072. Epub 2021 Sep 2. Cancer Discov. 2021. PMID: 34475136 Clinical Trial.
Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel.
Shachor-Meyouhas Y, Hussein K, Dabaja-Younis H, Szwarcwort-Cohen M, Almog R, Weissman A, Mekel M, Hyams G, Horowitz NA, Gepstein V, Netzer I, Saban HC, Petersiel N, Tarabeia J, Halberthal M. Shachor-Meyouhas Y, et al. Among authors: almog r. Clin Microbiol Infect. 2022 Mar;28(3):450.e1-450.e4. doi: 10.1016/j.cmi.2021.11.014. Epub 2021 Nov 24. Clin Microbiol Infect. 2022. PMID: 34838782 Free PMC article.
Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers.
Hussein K, Dabaja-Younis H, Szwarcwort-Cohen M, Almog R, Leiba R, Weissman A, Mekel M, Hyams G, Horowitz NA, Gepstein V, Cohen Saban H, Tarabeia J, Halberthal M, Shachor-Meyouhas Y. Hussein K, et al. Among authors: almog r. Vaccines (Basel). 2022 Oct 18;10(10):1741. doi: 10.3390/vaccines10101741. Vaccines (Basel). 2022. PMID: 36298606 Free PMC article.
Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers.
Shachor-Meyouhas Y, Dabaja-Younis H, Magid A, Leiba R, Szwarcwort-Cohen M, Almog R, Mekel M, Weissman A, Hyams G, Gepstein V, Horowitz NA, Cohen Saban H, Tarabeia J, Halberthal M, Hussein K. Shachor-Meyouhas Y, et al. Among authors: almog r. Vaccines (Basel). 2023 Jan 28;11(2):283. doi: 10.3390/vaccines11020283. Vaccines (Basel). 2023. PMID: 36851161 Free PMC article.
Comparing COVID-19 and Influenza Presentation and Trajectory.
Reiner Benaim A, Sobel JA, Almog R, Lugassy S, Ben Shabbat T, Johnson A, Eytan D, Behar JA. Reiner Benaim A, et al. Among authors: almog r. Front Med (Lausanne). 2021 May 14;8:656405. doi: 10.3389/fmed.2021.656405. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34055833 Free PMC article.
95 results